Aker BioMarine ASA

As of June 30, 2025, Aker BioMarine ASA carries a market capitalization of 438.43M, placing it among publicly traded companies globally. Its enterprise value stands at 577.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aker BioMarine ASA's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2025, Aker BioMarine ASA has 87.69M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Aker BioMarine ASA maintains a current ratio of 2.63, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Aker BioMarine ASA recorded an income tax benefit of -254,550.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 1, 2026, Aker BioMarine ASA's stock has gained approximately 35.25% over the past 52 weeks. The 50-day moving average sits at 11.28, while the 200-day moving average is 9.59.

As of June 30, 2025, Aker BioMarine ASA holds 16.55M in cash and equivalents against 155.36M in total debt, resulting in a net debt position of -16.55M. Total book value stands at 126.94M, with working capital of 102.33M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Aker BioMarine ASA paid dividends of 3.80 per share.